The GI-4000 therapeutic vaccine or placebo will be injected under the skin of post-resection, non-metastatic pancreas cancer patients. Patients will be monitored for recurrence as well as safety, and immune responses related to the injections.

(A few general items required)

Inclusion Criteria:

• Patients with non-metastatic pancreas cancer post-resection that have a product-related ras mutation
• >18 years of age
• Negative skin test for hypersensitivity to Saccharomyces cerevisiae

Exclusion Criteria:

• Metastatic pancreas cancer patients post-resection
• Patients with no product-related ras mutation.